Monday 01 December 2025
Internal Reference Number: FOI_8939
Date Request Received: 02/10/2025 00:00:00
Date Request Replied To: 16/10/2025 00:00:00
This response was sent via: By Email
Request Summary: biologic medicines in gastroenterology
Request Category: Companies
| Question Number 1: How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Etrasimod • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab - Stelara • Ustekinumab Biosimilar • Vedolizumab | |
| Answer To Question 1: Please see our response to both questions in the attached file. To accompany this answer to question 1 please also see the documents listed below:  13279 - FOI_8939 - Biologic medicines in gastroenterology FOR ISSUE.xlsx | |
| Question Number 2: Could you please provide the numbers of patients treated for Crohn’s Disease in the last 3 months with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilars • Golimumab • Infliximab - Remicade • Infliximab Biosimilars • Risankizumab • Upadacitinib • Ustekinumab - Stelara • Ustekinumab Biosimilar • Vedolizumab • Mirikizumab | |
| Answer To Question 2: Please see attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
